

DIAGNOS

Interim Condensed Consolidated Financial Statements – Unaudited
Three-month and Nine-month Periods ended December 31, 2021

DIAGNOS Inc.

Note to reader: These Interim Condensed Consolidated Financial Statements have not been audited or reviewed by our auditor.

DIAGNOS Inc.
Interim Consolidated Statements of Financial Position
(amounts in Canadian dollars)

| | Note | As at | |
|---|------|-------------------------|-------------------------|
| | | December 31, 2021 | March 31, 2021 |
| | | \$ | |
| ASSETS | | | |
| Current | | | |
| Cash | | 503,329 | 359,390 |
| Short-term investments | | - | 1,001,467 |
| Accounts receivable | 6 | 266,374 | 203,992 |
| Prepaid expenses | | 43,183 | 26,115 |
| | | <u>812,886</u> | <u>1,590,964</u> |
| Non-current | | | |
| Investments | | - | 31,811 |
| Capital assets | | 272,776 | 327,567 |
| | | <u>272,776</u> | <u>359,378</u> |
| Total assets | | <u>1,085,662</u> | <u>1,950,342</u> |
| LIABILITIES | | | |
| Current | | | |
| Accounts payable and accrued liabilities | 7 | 329,975 | 342,340 |
| Deferred revenue | | 8,894 | 4,167 |
| Loans | 8 | 125,000 | 125,000 |
| Leases | | 68,269 | 78,556 |
| | | <u>532,138</u> | <u>550,063</u> |
| Non-current | | | |
| Leases | | 178,714 | 228,960 |
| Loans | 8 | 158,522 | 39,166 |
| | | <u>337,236</u> | <u>268,126</u> |
| Total liabilities | | <u>869,374</u> | <u>818,189</u> |
| SHAREHOLDERS' EQUITY | | | |
| Share capital | 9 | 35,575,775 | 34,756,759 |
| Reserve | 10 | 8,883,418 | 8,737,350 |
| Deficit | | (44,267,067) | (42,384,244) |
| Investments revaluation reserve | | (53,082) | (53,082) |
| Foreign exchange differences | | 77,244 | 75,370 |
| | | <u>216,288</u> | <u>1,132,153</u> |
| Total liabilities and shareholders' equity | | <u>1,085,662</u> | <u>1,950,342</u> |

The accompanying notes are an integral part of these interim consolidated financial statements.

Approved by the Board of Directors:

(signed) Vincent Duhamel
Acting chairman

(signed) André Larente
Director

DIAGNOS Inc.
Interim Consolidated Statements of Loss and Comprehensive Loss
(amounts in Canadian dollars)

| | Note | Three-month period ended December 31, | | Nine-month period ended December 31, | |
|---|------|--|-------------------|---|--------------------|
| | | 2021 | 2020 | 2021 | 2020 |
| | | \$ | | \$ | |
| Revenue | 12 | 129,836 | 77,877 | 286,730 | 205,354 |
| Expenses | | | | | |
| Costs of services and research and development | | 236,874 | 164,042 | 666,110 | 428,528 |
| Selling and administrative | | 492,583 | 482,589 | 1,568,409 | 1,419,105 |
| | | <u>729,457</u> | <u>646,631</u> | <u>2,234,519</u> | <u>1,847,633</u> |
| Loss before other items | | (599,621) | (568,754) | (1,947,789) | (1,642,279) |
| Other income | 14 | 3,000 | 12,149 | 92,829 | 259,179 |
| Interest expense | | <u>(8,473)</u> | <u>(16,174)</u> | <u>(27,863)</u> | <u>(38,179)</u> |
| Net loss | | (605,094) | (572,779) | (1,882,823) | (1,421,279) |
| Other comprehensive income items | | | | | |
| Net change in foreign exchange translation | | <u>(1)</u> | <u>15,575</u> | <u>1,874</u> | <u>(8,421)</u> |
| Comprehensive loss | | (605,095) | (557,204) | (1,880,949) | (1,429,700) |
| Basic and diluted net loss per share | | (0.01) | (0.01) | (0.03) | (0.02) |
| Weighted-average number of common shares outstanding | | <u>69,119,982</u> | <u>63,590,672</u> | <u>68,535,730</u> | <u>62,112,973</u> |

The accompanying notes are an integral part of these interim consolidated financial statements.

DIAGNOS Inc.

Interim Consolidated Statements of Changes in Equity

(amounts in Canadian dollars)

Nine-month period ended December 31, 2021

| | Note | Share capital | Reserve | Deficit | Investments revaluation reserve | Foreign exchange differences | Total shareholders' equity |
|-------------------------------------|-------|-------------------|------------------|---------------------|---------------------------------------|------------------------------------|----------------------------------|
| \$ | | | | | | | |
| Balance, beginning of period | | 34,756,759 | 8,737,350 | (42,384,244) | (53,082) | 75,370 | 1,132,153 |
| Net loss | | - | - | (1,882,823) | - | - | (1,882,823) |
| Other comprehensive loss items | | - | - | - | - | 1,874 | 1,874 |
| Issuance of common shares | 9, 10 | 819,016 | (166,016) | - | - | - | 653,000 |
| Stock-based compensation expense | 10 | - | 312,084 | - | - | - | 312,084 |
| Balance, end of period | | 35,575,775 | 8,883,418 | (44,267,067) | (53,082) | 77,244 | 216,288 |

Nine-month period ended December 31, 2020

| | Note | Share capital | Reserve | Deficit | Investments revaluation reserve | Foreign exchange differences | Total shareholders' equity |
|-------------------------------------|------|-------------------|------------------|---------------------|---------------------------------------|------------------------------------|----------------------------------|
| \$ | | | | | | | |
| Balance, beginning of period | | 33,666,631 | 8,468,301 | (40,332,941) | (53,082) | 70,262 | 1,819,171 |
| Net loss | | - | - | (1,421,279) | - | - | (1,421,279) |
| Other comprehensive loss items | | - | - | - | - | (8,421) | (8,421) |
| Issuance of common shares | 9 | 687,740 | - | - | - | - | 687,740 |
| Stock-based compensation expense | 10 | - | 89,928 | - | - | - | 89,928 |
| Balance, end of period | | 34,354,371 | 8,558,229 | (41,754,220) | (53,082) | 61,841 | 1,167,139 |

The accompanying notes are an integral part of these interim consolidated financial statements.

DIAGNOS Inc.
Interim Consolidated Statements of Cash Flows
(amounts in Canadian dollars)

| | Nine-month period ended December 31, | | |
|---|--------------------------------------|---------------------------|-------------------------|
| | Note | 2021 | 2020 |
| | | \$ | |
| Cash flows from operating activities | | | |
| Net loss | | (1,882,823) | (1,421,279) |
| Items not affecting cash | | | |
| Depreciation of capital assets | | 78,435 | 49,913 |
| Accretion on loans | | - | 3,289 |
| Accretion on leases | | 21,329 | 243 |
| Accretion on convertible notes | | - | 6,503 |
| Accretion on governmental loan | | 2,781 | - |
| Governmental grant amortization | | (2,890) | (3,980) |
| Stock-based compensation expense | 10 | 312,084 | 89,928 |
| | | <u>(1,471,084)</u> | <u>(1,275,383)</u> |
| Payment of interest | | 8,044 | 33,996 |
| Net change in operating working capital items | | (87,088) | 372,970 |
| | | <u>(1,550,128)</u> | <u>(868,417)</u> |
| Cash flows from investing activities | | | |
| Proceeds from disposal of short-term investments | | 1,200,000 | 800,000 |
| Acquisition of short-term investments | | (200,000) | - |
| Proceeds from disposal of investments | | 30,000 | - |
| Interest on investments | | 3,278 | - |
| Additions to capital assets | | (23,644) | (24,639) |
| Foreign exchange translation | | 1,874 | - |
| Other | | - | (8,421) |
| | | <u>1,011,508</u> | <u>766,940</u> |
| Cash flows from financing activities | | | |
| Issuance of common shares | | 653,000 | - |
| Issuance of common shares and warrants, net of issue expenses | | - | 687,740 |
| Repayment of convertible notes | | - | (150,000) |
| Loan | 8 | 119,465 | 40,000 |
| Lease payments | | (81,862) | (54,280) |
| Payment of interest | | (8,044) | (33,996) |
| | | <u>682,559</u> | <u>489,464</u> |
| Net change in cash | | 143,939 | 387,987 |
| Cash, beginning of period | | 359,390 | 570,442 |
| Cash, end of period | | <u>503,329</u> | <u>958,429</u> |

The accompanying notes are an integral part of these interim consolidated financial statements.

Notes to the Interim Consolidated Financial Statements

December 31, 2021, March 31, 2021 and December 31, 2020

(amounts in Canadian dollars)

1. Going concern assumption

These interim consolidated financial statements have been prepared on a going concern basis, which assumes that the Corporation will continue to operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

The Corporation's current level of revenue is not sufficient to cover its expenses and ongoing commitments. The Corporation's ability to generate positive cash flows from its operating activities is dependent on achieving and maintaining profitable operations. Until it is able to generate positive cash flows from its operating activities, the Corporation will need, from time to time, to raise funds through financing activities.

Since inception, the Corporation has been able to finance its activities and operate on a going concern basis through issuances of common shares, stock warrants, convertible notes, convertible debentures and demand loans. While the Corporation has been successful in securing financing in the past, there can be no assurance it will be able to do so in the future, that such sources of funding or initiatives will be available on terms acceptable to the Corporation. If the Corporation is unable to obtain sufficient additional funding, it may be unable to continue its operations, and amounts from the sale of assets might be less than the amounts reflected in these interim consolidated financial statements.

These interim consolidated financial statements do not reflect any adjustments that would be necessary if the going concern basis was not appropriate. Such adjustments, if required, may be material.

2. Statutes of incorporation and nature of activities

DIAGNOS Inc. ("the Corporation") is incorporated under the Canada Business Corporations Act and the subsidiaries under the applicable regulations in their respective countries. The main office is located at 7005 Taschereau Blvd., Suite 265, Brossard, Quebec, Canada. The shares of the Corporation are listed on the TSX Venture Exchange.

The Corporation provides software-based services to assist health specialists in the detection of diabetic retinopathy.

These interim consolidated financial statements have been approved and authorized for filing by the Board of Directors of the Corporation on February 28, 2022.

3. Basis of consolidation, statement of compliance with IFRS and summary of accounting policies

Basis of consolidation

These interim consolidated financial statements include the accounts of the Corporation and those of its subsidiaries. Subsidiaries consist of entities over which the Corporation has right, or is exposed, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Subsidiaries' financial statements are included in the consolidated financial statements from the date that control commences until the date that control ceases. Subsidiaries' year end and accounting policies are aligned with those adopted by the Corporation.

Percentages of ownership in the Corporation's subsidiaries are as follows:

| Name of subsidiary | Location of subsidiary | Percentage of ownership in subsidiary |
|--|------------------------|---------------------------------------|
| Diagnos Internacional SA de CV | Mexico | 99.8% |
| Diagnos Healthcare (India) Private Limited | India | 99.74% |

Diagnos Poland sp. Z.o.o. was liquidated on July 9, 2021. Diagnos Healthcare (India) Private Limited liquidation process has been started.

Inter-company transactions and balances and any unrealized revenue and expense are eliminated in preparing the consolidated financial statements.

DIAGNOS Inc.

Summary of accounting policies

These interim condensed consolidated financial statements were prepared in accordance with standard IAS 34 – Interim Financial Reporting and do not include all of the information required for a full set of financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”). They, however, include specific complimentary notes in order to provide information necessary to assess the financial situation of the Corporation at period end since its last annual consolidated financial statements dated March 31, 2021.

The accounting policies used to prepare these interim condensed consolidated financial statements are those described in the last annual consolidated financial statements of the Corporation and have been applied throughout the period unless otherwise stated.

4. Critical accounting judgments and key sources of estimation uncertainty

In preparing these interim condensed consolidated financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgments made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

5. Significant events during the period covered by these interim condensed consolidated financial statements

Pandemic

The Corporation’s sales process continues to be somewhat impacted by the COVID-19 pandemic. However, it has not significantly impacted our ability to maintain our operations. The Corporation was able to retain all of its key employees and to qualify for various federal financial relief programs. Unchanged from the last reporting period, the Corporation is monitoring the situation closely and may take additional measures to reduce its costs and preserve its liquidities.

Financing activities

During the quarter ended December 31, 2021, the Corporation received a first disbursement of \$119,465 under a financing agreement in the form of an interest-free loan of up to \$2,000,000 from the government of Québec via the Economic Development Fund to support the commercialization of its healthcare services globally. The disbursements are in the form of installments corresponding to 49% of the eligible expenses incurred up to June 30, 2022 for which the Corporation is requesting disbursement. The interest-free loan has a term of 10 years and principal repayment will start after the 24th month following the first disbursement.

During the six-month period ended September 30, 2021, the Corporation received an aggregate amount of \$653,000 resulting from the exercises of stock warrants and stock options.

DIAGNOS Inc.

6. Accounts receivable

| | As at | |
|--|-------------------|----------------|
| | December 31, 2021 | March 31, 2021 |
| | \$ | |
| Customers | 60,147 | 26,961 |
| Tax credits on research and development expenses | 120,549 | 75,549 |
| Government grant | - | 10,746 |
| Demand loan bearing annual interest rate of 4% | 43,463 | 43,500 |
| Sales commissions advance, no interest bearing | 30,841 | 21,030 |
| Advance | 52 | 6,121 |
| Sales taxes | 9,837 | 18,790 |
| Deposits | 1,300 | 1,189 |
| Others | 185 | 106 |
| | 266,374 | 203,992 |

All amounts are due in the short term. The net carrying amounts are a reasonable approximation of their fair value.

7. Accounts payable and accrued liabilities

| | As at | |
|--|-------------------|----------------|
| | December 31, 2021 | March 31, 2021 |
| | \$ | |
| Accounts payable and accrued liabilities | 193,091 | 190,074 |
| Salaries and benefits | 136,781 | 152,163 |
| Interests payable and accrued | 103 | 103 |
| | 329,975 | 342,340 |

DIAGNOS Inc.

8. Loans

| | As at | |
|--|-------------------|----------------|
| | December 31, 2021 | March 31, 2021 |
| | \$ | |
| Unsecured non-convertible demand loans | 125,000 | 125,000 |
| Interest-free loan | 119,465 | - |
| fair value discount | (76,171) | - |
| deferred grant | 76,171 | - |
| Interest-free bank loan | 40,000 | 40,000 |
| fair value discount | (8,160) | (10,941) |
| deferred grant | 7,217 | 10,107 |
| | 283,522 | 164,166 |
| Short-term portion | 125,000 | 125,000 |
| Long-term portion | 158,522 | 39,166 |

During the period ended December 31, 2021, loans varied as follows:

| | Nine-month period ended December 31, | |
|-------------------------------------|--------------------------------------|----------------|
| | 2021 | 2020 |
| | \$ | |
| Balance, beginning of period | 164,166 | 125,000 |
| Proceeds from loan | 119,465 | - |
| Proceeds from bank loan | - | 40,000 |
| Accretion | 2,781 | 4,567 |
| Amortization of grant | (2,890) | (5,401) |
| Balance, end of period | 283,522 | 164,166 |

During the quarter ended December 31, 2021, the Corporation received a first disbursement of \$119,465 under a financing agreement in the form of an interest-free loan of up to \$2,000,000 from the government of Québec via the Economic Development Fund to support the commercialization of its healthcare services globally. The disbursements are in the form of installments corresponding to 49% of the eligible expenses incurred up to June 30, 2022 for which the Corporation is requesting disbursement. The interest-free loan has a term of 10 years and principal repayment will start after the 24th month following the first disbursement.

The fair value of the interest-free loan has been established at \$43,294 using the discounted cash flows valuation method with the following weighted average assumptions:

| | | | |
|-----------------------------|------------|--------------------------|--------|
| Maturity: | 10 years | Nominal interest rate: | 0% |
| Interest payment frequency: | 0 per year | Effective interest rate: | 18.51% |

During the quarter ended December 31, 2021, the maturity date of the unsecured non-convertible demand loans has been extended to December 16, 2022.

DIAGNOS Inc.

9. Share capital

Share capital is composed of common shares without par value of which 69,119,982 are issued and outstanding as at December 31, 2021 (March 31, 2021 – 67,303,982). All the shares have identical rights with respect to the distribution of dividends and the repayment of capital. Each share confers the right to one vote at the annual general meeting of shareholders. The Corporation is authorized to issue an unlimited number of common shares.

On April 24, 2019, the Corporation completed a one for ten share consolidation. As such, all references to common shares, warrants and stock options in these interim consolidated financial statements have been adjusted to reflect the share consolidation.

The following table presents the changes to share capital which have occurred during the period ended December 31, 2021:

| | Number of common shares | \$ |
|-------------------------------------|----------------------------|-------------------|
| Balance, beginning of period | 67,303,982 | 34,756,759 |
| Exercise of stock warrants | 966,000 | 598,016 |
| Exercise of stock options | 850,000 | 221,000 |
| Balance, end of period | 69,119,982 | 35,575,775 |

Stock option plan

The Corporation maintains a stock option plan for its directors, key employees and consultants. Stock option grants vest at 50% per year, commencing with the first anniversary of the grant and can be exercised over five years. The conditions of exercise are determined by the Board of Directors in accordance with the policies of the TSX Venture Exchange. The stock options are granted at or above the share price at the close of market on the day preceding the date of grant.

As at December 31, 2021, the outstanding number of stock options is 6,177,000 (March 31, 2021 – 7,722,000) and the outstanding number of stock options available for issuance is 2,715,909 (March 31, 2021 – 820,909).

10. Reserve

| | Nine-month period ended December 31, 2021 | | | |
|-------------------------------------|---|--------------------|------------------|------------------|
| | Stock warrants | Conversion options | Stock options | Total |
| | \$ | | | |
| Balance, beginning of period | 4,399,999 | 1,227,456 | 3,109,895 | 8,737,350 |
| Stock-based compensation | - | - | 312,084 | 312,084 |
| Exercises | (115,016) | - | (51,000) | (166,016) |
| Balance, end of period | 4,284,983 | 1,227,456 | 3,370,979 | 8,883,418 |

| | Nine-month period ended December 31, 2020 | | | |
|-------------------------------------|---|--------------------|------------------|------------------|
| | Stock warrants | Conversion options | Stock options | Total |
| | \$ | | | |
| Balance, beginning of period | 4,375,037 | 1,227,456 | 2,865,808 | 8,468,301 |
| Stock-based compensation | - | - | 89,928 | 89,928 |
| Balance, end of period | 4,375,037 | 1,227,456 | 2,955,736 | 8,558,229 |

11. Financial instruments and risk management

The Corporation is exposed to certain risks which could have a material impact on its ability to achieve its strategic growth objectives. The Corporation strives to control and mitigate its business and financial risks through management practices that require the ongoing evaluation, identification and implementation of risk mitigating measures that help reduce or eliminate risks related to its business operations.

The following describes the Corporation's main financial risks:

i. Credit Risks

In the normal course of business, the Corporation's exposure to credit risk results from the possibility that a customer or financial institution may default, in part or in whole, on their financial obligations, as they come due.

Cash and short-term investments

Cash as well as short-term investments are mainly risk-free or low-risk investments, such as cash and guaranteed term deposits held by recognized financial institutions. Consequently, management considers the credit risk related to cash and short-term investments to be low as at December 31, 2021 and March 31, 2021.

Clients, advances and demand loan

The Corporation determines whether the credit risk of a financial asset has increased significantly since initial recognition considering reasonable and supportable information that is relevant and available without undue cost or effort, this includes both quantitative and qualitative information and analysis, based on the historical experience and informed assessment and including forward-looking information.

Management is reasonably assured that its receivables will be collected and therefore considers the credit risk related to accounts receivable to be low as at December 31, 2021 and March 31, 2021.

ii. Liquidity Risks

Liquidity risk is the risk that the Corporation cannot meet its obligations as they come due. On an ongoing basis, the Corporation monitors and manages its actual and projected cash flows, with the primary objectives of maintaining liquidity and financial flexibility. In addition, the Corporation's policy is to target contracts that will generate positive cash flows throughout their execution.

Considering the available liquidities to meet its short-term obligations, the Corporation's exposure to liquidity risk as at December 31, 2021 and March 31, 2021 is high. Moreover, meeting long-term obligations is dependent on the Corporation's ability in securing additional financing and achieving and maintaining profitable operations (refer to going concern assumptions in note 1).

iii. Interest Rate Risk

Interest rate risk refers to the adverse consequences of interest rate changes on the Corporation's cash flows, financial position and income. Interest rate changes directly impact the fair value of the fixed interest rate accounts of the financial statements.

The Corporation is not exposed to interest risk since its financial instruments bear interest at fixed rate and are presented at amortized cost.

iv. Other Price Risk

Other price risk refers to the adverse consequences of stock price changes on the Corporation's investments in shares. As at December 31, 2021 and March 31, 2021, the Corporation is not exposed to price risk since its investments in shares are valued at \$0.

v. Exchange Rate Fluctuations Risk

Exchange rate fluctuations risk refers to the adverse consequences of exchange rate changes on the Corporation's cash flows, financial position and income. During the year, revenues and expenses arose from transactions occurring mainly in Canadian dollars.

The Corporation is mainly exposed to fluctuations in the US currency rate. Movements in foreign currencies against the Canadian dollar may impact revenues, the nominal amount of certain financial assets and financial liabilities, and negatively affect the Corporation's profit or loss.

Assuming that all other variables remain constant, a 10% increase or decrease in the exchange rate of the Canadian dollar, against other currencies, would not have a significant impact on the Corporation's net loss and equity for the nine-month periods ended December 31, 2021 and December 31, 2020.

12. Segment information

The Corporation is active in one reportable segment, healthcare services.

Revenue by country:

| | Three-month period ended December | | Nine-month period ended December | |
|--------------------------|-----------------------------------|---------------|----------------------------------|----------------|
| | 31, | | 31, | |
| | 2021 | 2020 | 2021 | 2020 |
| | \$ | | \$ | |
| Canada | 123,608 | 71,116 | 264,131 | 168,578 |
| United States of America | 4,805 | 5,831 | 19,688 | 33,969 |
| Saudi Arabia | 305 | - | 1,052 | - |
| Mexico | 939 | - | 1,290 | - |
| Costa Rica | 66 | - | 314 | - |
| Colombia | 9 | 930 | 93 | 2,807 |
| Spain | 104 | - | 162 | - |
| | <u>129,836</u> | <u>77,877</u> | <u>286,730</u> | <u>205,354</u> |

For the nine-month period ended December 31, 2021, 13% of revenues from Canada were attributable to data analysis consulting services rendered to one company active in the mining sector (nine-month period ended December 31, 2020 – 80%).

13. Related party transactions

The Corporation's related parties include its subsidiaries and associate entity as well as the Corporation's key management personnel. Key management personnel include directors and officers.

The following table presents the transactions with key management personnel:

| | Three-month period ended December | | Nine-month period ended December | |
|------------------------------------|-----------------------------------|----------------|----------------------------------|----------------|
| | 31, | | 31, | |
| | 2021 | 2020 | 2021 | 2020 |
| | \$ | | \$ | |
| Base salary | 193,333 | 109,543 | 297,083 | 323,918 |
| Stock-based compensation | 163,789 | 23,425 | 245,684 | 67,033 |
| Incentives | 10,000 | - | 10,000 | 50,000 |
| Loan | 10,000 | - | 10,000 | - |
| Interest on demand loan | 870 | 485 | 1,305 | 1,455 |
| Payment of interest on demand loan | (870) | (485) | (1,305) | (1,455) |
| | <u>377,122</u> | <u>132,968</u> | <u>562,767</u> | <u>440,951</u> |

The following table present the outstanding balances with key management personnel:

| | As at | |
|--|-------------------|----------------|
| | December 31, 2021 | March 31, 2021 |
| | \$ | |
| Demand loan receivable, annual interest rate of 4% | 43,500 | 43,500 |
| Sales commission advance, no interest | 20,841 | 20,841 |
| Loan, no interest bearing | 10,000 | - |

14. Other income

Government assistance program

During the nine-month period ended December 31, 2021, the Corporation recognized an amount of \$77,939 from the Canada Emergency Wage Subsidy program (nine-month period ended December 31, 2020 - \$249,199).

15. Subsequent event

In the month of February 2022, the Corporation received an aggregate amount of \$70,834 from the exercise of stock warrants.

Head Office

DIAGNOS Inc.
7005 Taschereau Blvd.
Suite 265
Brossard, Quebec J4Z 1A7
450 678-8882 or 877 678-8882

Stock Exchange Listing

The common shares of DIAGNOS Inc. are listed on the TSX Venture Exchange under the symbol ADK and on the OTCQB under the symbol DGNOF.

Transfer Agents and Registrar

Computershare Trust Company of Canada

Auditor

Raymond Chabot Grant Thornton LLP